Harrow rises after H.C. Wainwright starts coverage with 'buy' rating

Harrow

06/02/2025 15:30

** Eye-drug maker Harrow's  HROW  shares rise 2.09% to
$31.32
    ** Brokerage H.C. Wainwright starts coverage on HROW with
"buy" rating; sets PT at $57
    ** Brokerage sees rapid growth driven by co's branded
products for eye diseases 
    ** Expects HROW to continue to make meaningful and sensible
buys
    ** Says its eye drop Vevye compares well to other dry eye
treatments
    ** Says that other eye products that are used during
surgical procedures such as Iheezo and Triesence also serve as
growth drivers
    ** The PT is a 84.5% upside to the stock's last close
    ** Stock rose ~232% in the last 12 months

 (Reporting by Siddhi Mahatole)
 ((siddhiprabhanjan.mahatole@thomsonreuters.com))